Fan Yang

• Deal Leadership: Independently lead and execute end-to-end legal strategy for complex global transactions across North America, Europe, Asia and Latin America
• Strategic Advisory: Serve as a core legal partner to BD, Finance, Tax, Commercial, Supply Chain and R&D stakeholders to align transaction structures with global business objectives
• Antitrust & Risk Management: Drive negotiation strategy and risk allocation for multi-jurisdictional deals, ensuring robust governance and compliance
• Operational Excellence: Oversee a global contracting portfolio, managing high-priority agreements for supply, distribution and clinical operations
• Team Leadership: Manage a high-performing transactions legal team, ensuring scalable execution of concurrent multi-billion-dollar deals

Selected Transactions:

• Ongoing Multi-Billion Dollar Strategic Transactions: Lead global legal workstreams for two confidential multi-billion dollar deals; drive complex deal structuring, cross-boarder diligence coordination, and negotiation strategy while ensuring alignment among executive stakeholders
• Concert Pharmaceuticals (approximately $576M): Led legal workstream for the acquisition of this NASDAQ-listed entity, managing due diligence, negotiation, documentation, and post-closing integration
• Checkpoint Therapeutics ($355M+): Directed legal execution and negotiations for the acquisition of oncology assets; directed execution, negotiations, closing mechanics, and integration, specifically managing contingent value rights
• Alchemee (The Proactiv Company)/Taro Pharma: Led the legal execution of the acquisition of Galerma's Alchemee business; spearheaded the subsequent post-acquisition integration into the Taro business platform, ensuring seamless operational transition
• Taro take-private/delisting: Supported acquisition of outstanding shares owned by minority sharelders and NYSE delisting process
• Cassiopea Strategic Alliance (Winlevi): Negotiated the exclusive license and supply agreement for Winlevi across U.S., Canada, India, China and other jurisdictions
• Philogen Oncology Pipeline (Fibromun & Nidlegy™): Led legal negotiations for a worldwide exclusive license for Fibromun (L19TNF) and a multi-territory license (Europe, Australia, New Zealand) for Nidlegy™.

• Built and led the legal function across Hong Kong and mainland China; advised the Board, CEO and senior management on corporate governance, compliance, financing and strategic initiatives.
• Led asset in-licensing agreements and related arrangements (licenses, clinical supply, quality, PV, CMO) and supported clinical development activities across Greater China.

• Cross-Border Lead: Advised multinational corporations and private equity firms on complex outbound and inbound M&A, joint ventures, and strategic divestitures
• Sector Expertise: Specialized in the life sciences and technology sectors, leading legal due diligence, deal structuring, and regulatory filings for multi-jurisdictional transactions
• Governance & Compliance: Acted as outside general counsel for key clients, providing strategic advice on corporate governance, anti-corruption (FCPA) compliance, and IPO readiness

Managed regional investment projects and high-value commercial contracts for a Fortune 500 global leader, ensuring alignment between local operations and global corporate policy